Have a feature idea you'd love to see implemented?
Let us know!
BLRX Bioline Rx Ltd
Price (delayed)
$0.123
Market cap
$9.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.01
Enterprise value
$10.33M
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain
Highlights
BLRX's EPS has surged by 80% year-on-year and by 67% since the previous quarter
BLRX's net income has soared by 62% YoY and by 34% QoQ
The debt has surged by 122% year-on-year but it has declined by 5% since the previous quarter
The equity has contracted by 39% from the previous quarter and by 35% YoY
Bioline Rx's quick ratio has decreased by 25% YoY and by 8% QoQ
Key stats
What are the main financial stats of BLRX
Market
Valuations
Earnings
Shares outstanding
80.37M
Market cap
$9.88M
Enterprise value
$10.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
0.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
Revenue
$21.99M
Gross profit
$15.13M
Net income
-$19.92M
EBIT
-$16.21M
EBITDA
-$13.29M
Free cash flow
-$30.35M
Per share
Balance sheet
Liquidity
EPS
-$0.01
EPS diluted
-$0.01
Free cash flow per share
-$0.38
Book value per share
$0.11
Revenue per share
$0.27
TBVPS
$0.49
Total assets
$52.74M
Total liabilities
$44.24M
Debt
$29.61M
Equity
$8.51M
Working capital
$12.89M
Debt to equity
3.48
Current ratio
1.52
Quick ratio
1.33
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
-60.4%
Gross margin
68.8%
Net margin
-90.6%
Operating margin
-157.1%
Return on assets
-34.2%
Return on equity
-163.4%
Return on invested capital
N/A
Return on capital employed
-58.4%
Return on sales
-73.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLRX stock price
How has the Bioline Rx stock price performed over time
Intraday
-10.48%
1 week
-23.13%
1 month
-45.31%
1 year
-91.28%
YTD
-42.52%
QTD
-42.52%
Financial performance
How have Bioline Rx's revenue and profit performed over time
Revenue
$21.99M
Gross profit
$15.13M
Operating income
-$34.55M
Net income
-$19.92M
Gross margin
68.8%
Net margin
-90.6%
BLRX's net income has soared by 62% YoY and by 34% QoQ
The net margin has increased by 49% since the previous quarter
The company's gross profit rose by 37% QoQ
BLRX's operating margin is up by 35% since the previous quarter
Growth
What is Bioline Rx's growth rate over time
Valuation
What is Bioline Rx stock price valuation
P/E
N/A
P/B
1.16
P/S
0.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
BLRX's EPS has surged by 80% year-on-year and by 67% since the previous quarter
The stock's price to book (P/B) is 79% less than its last 4 quarters average of 5.4 and 55% less than its 5-year quarterly average of 2.6
The equity has contracted by 39% from the previous quarter and by 35% YoY
BLRX's P/S is 95% below its last 4 quarters average of 8.2
The revenue has grown by 29% from the previous quarter
Efficiency
How efficient is Bioline Rx business performance
BLRX's return on assets has surged by 58% year-on-year and by 34% since the previous quarter
BLRX's return on sales has surged by 54% since the previous quarter
Bioline Rx's return on equity has increased by 28% QoQ and by 3.3% YoY
Dividends
What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLRX.
Financial health
How did Bioline Rx financials performed over time
The company's total assets is 19% higher than its total liabilities
Bioline Rx's quick ratio has decreased by 25% YoY and by 8% QoQ
The company's current ratio fell by 22% YoY and by 6% QoQ
The debt has surged by 122% year-on-year but it has declined by 5% since the previous quarter
The debt to equity has soared by 55% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.